×
About 6,665 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  2,212 results

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not ...
https://clinicaltrials.gov/ct2/show/NCT03900715

Jan 11th, 2022 - Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platel...

Personal history of autoimmune disease and other medical conditions and risk of myelody...
https://doi.org/10.1016/j.canep.2021.102090
Cancer Epidemiology; Linabery AM, Roesler MA et. al.

Jan 8th, 2022 - Autoimmune diseases and hematopoietic malignancies are known to cluster within individuals, suggesting intertwined etiologies. A limited number of studies have evaluated pre-existing medical conditions as risk factors for myelodysplastic syndromes...

Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Mana...
https://doi.org/10.1002/ajh.26455
American Journal of Hematology; Patnaik MM, Tefferi A

Jan 6th, 2022 - Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (~15% over 3-5 years). D...

see more →

Guidelines  12 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 23rd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the Am... Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomiz...

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 4th, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Myelodysplastic syndromes: clinical practice guidelines in oncology.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000017
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Attar E et. al.

Jul 13th, 2013 - The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disord...

see more →

Drugs  36 results see all →

Clinicaltrials.gov  159 results

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not ...
https://clinicaltrials.gov/ct2/show/NCT03900715

Jan 11th, 2022 - Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platel...

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT03746041

Jan 5th, 2022 - The main objective of this study is to determine the safety and tolerability of combined abaloparatide + bevacizumab in MDS patients. This will be a single center, single arm, phase 1 trial in MDS patients. In cycle 1, patients will be treated wit...

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
https://clinicaltrials.gov/ct2/show/NCT05178342

Jan 5th, 2022 - Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS)

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

Jan 5th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
https://clinicaltrials.gov/ct2/show/NCT05175508

Jan 3rd, 2022 - Newly diagnosed unfit AML and Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria are unable to tolerate the intensive chemo-therapy regimens due to their old age and poor physical condition, resulting in lim...

see more →

News  241 results

Dr. McCloskey on the Utility of Decitabine Plus Cedazuridine in Lower-Risk MDS
https://www.onclive.com/view/dr-mccloskey-on-the-utility-of-decitabine-plus-cedazuridine-in-lower-risk-mds

Jan 7th, 2022 - James K. McCloskey, MD, chief, Leukemia Division, John Theurer Cancer Center, Hackensack Meridian Health, discusses the utility of decitabine plus cedazuridine (Inqovi) in lower-risk myelodysplastic syndromes (MDS), based on data from the long-ter...

Innovative Center Focuses on Phase I Trials
https://www.onclive.com/view/innovative-center-focuses-on-phase-i-trials

Jan 3rd, 2022 - Angela Alistar, MD Medical Director Gastrointestinal Medical Oncology Morristown Medical Center A partnership between a healthcare system in Morristown, New Jersey, and a genomics research institute in Phoenix, Arizona, has led to the ope...

Luspatercept Shows Impressive Responses, Tolerability in Low-Risk MDS
https://www.onclive.com/view/luspatercept-shows-impressive-responses-tolerability-in-low-risk-mds

Dec 22nd, 2021 - Luspatercept-aamt (Reblozyl) produced more durable responses compared with placebo in patients with lower-risk myelodysplastic syndrome (LR-MDS) and anemia that is refractory to or ineligible for erythropoiesis-stimulating agent (ESA) therapy, acc...

Precision medicine: A new approach to AML, other blood cancers
https://www.mdedge.com/hematology-oncology/article/249816/aml
Caleb Rans, PharmD

Dec 12th, 2021 - The emergence of precision medicine has ushered in a groundbreaking era for the treatment of myeloid malignancies, with the ability to integrate individual molecular data into patient care. Over the past decade, insights from research focusing on.

Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS
https://www.medscape.com/viewarticle/964653

Dec 12th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Factors associated with the worst COVID-19-related outcomes for patients with acute leukemias and myelodysplastic syndromes include neutropenia, p...

see more →

Patient Education  6 results see all →